Vojtila, Lenka
Ashfaq, Iqra
Ampofo, Augustina
Dawson, Danielle
Selby, Peter https://orcid.org/0000-0001-5401-2996
Funding for this research was provided by:
Medical Psychiatry Alliance
Article History
Received: 11 September 2020
Accepted: 20 December 2020
First Online: 8 January 2021
Ethics approval and consent to participate
: Ethics approval was obtained for the mentioned TECC-Y study, to which this paper is a descriptive extension of (REB: #121–2017; Centre for Addiction and Mental Health). Augustina Ampofo provided consent to provide her personal accounts as a person with lived experience on the research team in this study.
: Not applicable.
: LV, IA, AA, and DD declare that they have no competing interests. PS reports receiving grants and/or salary and/or research support from the Centre for Addiction and Mental Health, Health Canada, Ontario Ministry of Health and Long-term care (MOHLTC), Canadian Institutes of Health Research (CIHR), Canadian Centre on Substance Use and Addiction, Public Health Agency of Canada (PHAC), Ontario Lung Association, Medical Psychiatry Alliance, Extensions for Community Healthcare Outcomes, Canadian Cancer Society Research Institute (CCSRI), Cancer Care Ontario, Ontario Institute for Cancer Research, Ontario Brain Institute, McLaughlin Centre, Academic Health Sciences Centre, Workplace Safety and Insurance Board, National Institutes of Health (NIH), and the Association of Faculties of Medicine of Canada. PS also reports receiving funding and/or honoraria from the following commercial organizations: Pfizer Inc./Canada, Shoppers Drug Mart, Bhasin Consulting Fund Inc., Patient-Centered Outcomes Research Institute, ABBVie, and Bristol-Myers Squibb. Further, PS reports receiving consulting fees from Pfizer Inc./Canada, Evidera Inc., Johnson & Johnson Group of Companies, Medcan Clinic, Inflexxion Inc., V-CC Systems Inc., MedPlan Communications, Kataka Medical Communications, Miller Medical Communications, Nvision Insight Group, and Sun Life Financial. Through an open tender process Johnson & Johnson, Novartis, and Pfizer Inc. are vendors of record for providing smoking cessation pharmacotherapy, free or discounted, for research studies in which PS is the principal investigator or co-investigator. PS reports receiving a grant from the Medical Psychiatry Alliance to support the study discussed in this manuscript. Through an open tender process Johnson & Johnson, Novartis, and Pfizer Inc. are vendors of record for providing smoking cessation pharmacotherapy, free or discounted, for research studies in which PS is the principal investigator or co-investigator.